Our results provide a plausible explanation of why CLL patients harboring miR-223 downregulation are associated with a poor outcome, pointing out HSP90B1 as a new pathogenic mechanism in CLL and a promising therapeutic target. The gene discussed is HSP90B1; the disease is B-cell chronic lymphocytic leukemia.